TapewireFind a company

person · Reporting owner

BLATT LAWRENCE

Disclosed activity across 1 company

Tapewire entity
61515
SEC CIK
0001242110

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aligos Therapeutics, Inc.ALGS · Entity 7352Director · President and CEOMarch 09, 2026March 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aligos Therapeutics, Inc.

Report date March 09, 2026 · Filed March 11, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.03 · Expires 2036-03-09Direct105,840 Reported balance After 2026-03-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-03-09 · Grant · Acquired 105,840 · Balance 105,840

F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 09, 2026 Filed Mar 11, 2026 20:13 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 105,840 $0.00 Strike: $7.03 $0.00
Disclosure

SEC source: 0001610717-26-000092 · form4.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,840

Underlying: Common Stock · 105,840 shares

Expires 2036-03-09

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
July 16, 2025 Filed Jul 18, 2025 21:14 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 179,800 $0.00 Strike: $8.68 $0.00
Disclosure

SEC source: 0001610717-25-000290 · form4.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,800

Underlying: Common Stock · 179,800 shares

Expires 2035-07-16

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 21:33 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 140,103 $0.00 Strike: $16.87 $0.00
Disclosure

SEC source: 0001610717-25-000046 · form4.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,103

Underlying: Common Stock · 140,103 shares

Expires 2035-02-28

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
September 04, 2024 Filed Sep 6, 2024 20:23 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 33,920 $0.00 Strike: $11.74 $0.00
Disclosure

SEC source: 0001610717-24-000465 · form4.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,920

Underlying: Common Stock · 33,920 shares

Expires 2034-09-04

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
March 01, 2024 Filed Mar 4, 2024 22:41 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 965,435 $0.00 Strike: $1.13 $0.00
Disclosure

SEC source: 0001610717-24-000121 · form4.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 965,435

Underlying: Common Stock · 965,435 shares

Expires 2024-03-01

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 22:32 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 57,749 $0.00 Strike: $0.96 $0.00
Disclosure

SEC source: 0001610717-24-000098 · form4.xml · derivative · entry 6

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,749

Underlying: Common Stock · 57,749 shares

Expires 2032-02-04

F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share.

F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 22:32 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 230,999 $0.00 Strike: $0.96 $0.00
Disclosure

SEC source: 0001610717-24-000098 · form4.xml · derivative · entry 5

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,999

Underlying: Common Stock · 230,999 shares

Expires 2032-02-04

F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share.

F5 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 22:32 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 132,352 $0.00 Strike: $0.96 $0.00
Disclosure

SEC source: 0001610717-24-000098 · form4.xml · derivative · entry 4

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,352

Underlying: Common Stock · 132,352 shares

Expires 2030-12-01

F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share.

F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 22:32 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 Disposition to issuerStock Option (Right to Buy) · Derivative 80,850 $0.00 Strike: $3.06 $0.00
Disclosure

SEC source: 0001610717-24-000098 · form4.xml · derivative · entry 3

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 80,850 shares

Expires 2032-02-04

F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 22:32 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 Disposition to issuerStock Option (Right to Buy) · Derivative 323,400 $0.00 Strike: $3.06 $0.00
Disclosure

SEC source: 0001610717-24-000098 · form4.xml · derivative · entry 2

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 323,400 shares

Expires 2032-02-04

F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 22:32 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 Disposition to issuerStock Option (Right to Buy) · Derivative 450,000 $0.00 Strike: $16.18 $0.00
Disclosure

SEC source: 0001610717-24-000098 · form4.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 450,000 shares

Expires 2030-12-01

F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share.

Read SEC document
October 25, 2023 Filed Oct 27, 2023 20:14 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantWarrants (Right to Buy) · Derivative 305,138 $0.13 Strike: $0.76 $38,142.25
Disclosure

SEC source: 0001610717-23-000319 · form4.xml · derivative · entry 6

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,138

Underlying: Common Stock · 305,138 shares

Expires 2030-10-25

Read SEC document
October 25, 2023 Filed Oct 27, 2023 20:14 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantCommon Stock 610,277 $0.76 $461,857.63
Disclosure

SEC source: 0001610717-23-000319 · form4.xml · nonDerivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,847,575

Read SEC document
September 08, 2023 Filed Sep 12, 2023 20:05 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 150,000 $0.00 Strike: $0.84 $0.00
Disclosure

SEC source: 0001610717-23-000273 · form4.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-09-08

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
March 15, 2023 Filed Mar 17, 2023 20:09 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 242,500 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001567619-23-005251 · doc1.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,500

Underlying: Common Stock · 242,500 shares

Expires 2033-03-15

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
July 07, 2022 Filed Jul 11, 2022 20:13 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 161,700 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001567619-22-013866 · doc1.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,700

Underlying: Common Stock · 161,700 shares

Expires 2032-07-07

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
February 04, 2022 Filed Feb 8, 2022 21:09 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 80,850 $0.00 Strike: $3.06 $0.00
Disclosure

SEC source: 0001567619-22-002892 · doc1.xml · derivative · entry 2

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,850

Underlying: Common Stock · 80,850 shares

Expires 2032-02-04

F2 · derivative.exercise_date: 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date.

Read SEC document
February 04, 2022 Filed Feb 8, 2022 21:09 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 323,400 $0.00 Strike: $3.06 $0.00
Disclosure

SEC source: 0001567619-22-002892 · doc1.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 323,400

Underlying: Common Stock · 323,400 shares

Expires 2032-02-04

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:03 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 450,000 $0.00 Strike: $16.18 $0.00
Disclosure

SEC source: 0001567619-20-020621 · doc1.xml · derivative · entry 1

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires 2030-12-01

F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries B-2 Preferred Stock · Derivative 1,452 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 21

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,452 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F5 · ownership.nature: Zoe Anne Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries B-2 Preferred Stock · Derivative 1,452 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 20

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,452 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F4 · ownership.nature: Zachary David Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries B-2 Preferred Stock · Derivative 21,695 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 19

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 21,695 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: Lawrence M. Blatt Living Trust dated 8/27/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries B-1 Preferred Stock · Derivative 3,394 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 18

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,394 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F5 · ownership.nature: Zoe Anne Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries B-1 Preferred Stock · Derivative 3,394 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 17

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,394 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F4 · ownership.nature: Zachary David Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries B-1 Preferred Stock · Derivative 50,712 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 16

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 50,712 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: Lawrence M. Blatt Living Trust dated 8/27/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries A Preferred Stock · Derivative 13,671 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 15

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 13,671 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F5 · ownership.nature: Zoe Anne Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries A Preferred Stock · Derivative 13,671 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 14

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 13,671 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F4 · ownership.nature: Zachary David Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries A Preferred Stock · Derivative 122,601 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 13

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 122,601 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F3 · ownership.nature: PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionSeries A Preferred Stock · Derivative 41,016 $0.00 $0.00
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · derivative · entry 12

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 41,016 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: Lawrence M. Blatt Living Trust dated 8/27/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 1,452 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 11

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 18,517

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F5 · ownership.nature: Zoe Anne Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 1,452 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 10

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 18,517

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F4 · ownership.nature: Zachary David Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 21,695 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 9

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 113,423

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: Lawrence M. Blatt Living Trust dated 8/27/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 3,394 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 8

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 17,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F5 · ownership.nature: Zoe Anne Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 3,394 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 7

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 17,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F4 · ownership.nature: Zachary David Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 50,712 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 6

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 91,728

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: Lawrence M. Blatt Living Trust dated 8/27/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 13,671 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 5

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,671

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F5 · ownership.nature: Zoe Anne Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 13,671 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 4

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,671

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F4 · ownership.nature: Zachary David Blatt Irrevocable Trust dated 8/24/14.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 122,601 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 3

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 122,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F3 · ownership.nature: PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA

Read SEC document
October 20, 2020 Filed Oct 20, 2020 20:55 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 ConversionCommon Stock 41,016 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-20-018001 · doc1.xml · nonDerivative · entry 2

BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 41,016

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: Lawrence M. Blatt Living Trust dated 8/27/14.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.